In this study, we report on pyrazin-2(1 H)-ones as lead for the development of potent adenosine triphosphate (ATP) competitive protein kinase inhibitors with implications as anti-cancer drugs. Initially, we identified the pyrazin-2(1 H)-one scaffold from hamacanthins (deep sea marine sponge alkaloids) by Molecular Modeling studies as core binding motif in the ATP pocket of receptor tyrosine kinases (RTK), which are validated drug targets for the treatment of various neoplastic diseases. Structure-based design studies on a human RTK member PDGFR (platelet-derived growth factor receptor) suggested a straight forward lead optimization strategy. Accordingly, we focused on a Medicinal Chemistry project to develop pyrazin-2(1 H)-ones as optimized PDGFR binders. In order to reveal Structure-Activity-Relationships (SAR), we established a flexible synthetic route via microwave mediated ring closure to asymmetric 3,5-substituted pyrazin-2(1 H)-ones and produced a set of novel compounds. Herein, we identified highly potent PDGFR binders with IC 50 values in an enzymatic assay below μM range, and possessing significant activity against PDGFR dependent cancer cells. Thus, marine hamacanthin-derived pyrazin-2(1 H)-ones showing interesting properties as lead for their further development towards potent PDGFR-inhibitors.
References
[1]
Haefner, B. Drugs from the deep: Marine natural products as drug candidates. Drug Discov. Today 2003, 8, 536–544, doi:10.1016/S1359-6446(03)02713-2.
[2]
Gupta, L.; Talwar, A.; Chauhan, P.M. Bis and tris indole alkaloids from marine organisms: New leads for drug discovery. Curr. Med. Chem. 2007, 14, 1789–1803, doi:10.2174/092986707781058904.
[3]
Skropeta, D.; Pastro, N.; Zivanovic, A. Kinase inhibitors from marine sponges. Mar. Drugs 2011, 9, 2131–2154, doi:10.3390/md9102131.
[4]
Kouko, T.; Matsumura, K.; Kawasaki, T. Total synthesis of marine bisindole alkaloids, (+)-hamacanthins A, B and (？)-antipode of cis-dihydrohamacanthin B. Tetrahedron 2005, 61, 2309–2318, doi:10.1016/j.tet.2005.01.058.
[5]
Bao, B.; Sun, Q.; Yao, X.; Hong, J.; Lee, C.-O.; Cho, H.Y.; Jung, J.H. Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp. J. Nat. Prod. 2007, 70, 2–8, doi:10.1021/np060206z.
[6]
Casapullo, A.; Bifulco, G.; Bruno, I.; Riccio, R. New bisindole alkaloids of the topsentin and hamacanthin classes from the Mediterranean marine sponge Rhaphisia lacazei. J. Nat. Prod. 2000, 63, 447–451, doi:10.1021/np9903292.
[7]
Peifer, C.; Bühler, S.; Hauser, D.; Kinkel, K.; Totzke, F.; Schaechtele, C.; Laufer, S. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors. Eur. J. Med. Chem. 2009, 44, 1788–1793, doi:10.1016/j.ejmech.2008.04.012.
[8]
Peifer, C.; Kinkel, K.; Abadleh, M.; Schollmeyer, D.; Laufer, S. From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. J. Med. Chem. 2007, 50, 1213–1221, doi:10.1021/jm061097o.
[9]
Peifer, C.; Krasowski, A.; H？mmerle, N.; Kohlbacher, O.; Dannhardt, G.; Totzke, F.; Schaechtele, C.; Laufer, S. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione(1) as a highly selective VEGF-R2/3 inhibitor. J. Med. Chem. 2006, 49, 7549–7553, doi:10.1021/jm0609871.
[10]
Peifer, C.; Selig, R.; Kinkel, K.; Ott, D.; Totzke, F.; Schaechtele, C.; Heidenreich, R.; R？cken, M.; Schollmeyer, D.; Laufer, S. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. J. Med. Chem. 2008, 51, 3814–3824, doi:10.1021/jm8001185.
[11]
Jiang, B.; Yang, C.G.; Wang, J. Enantioselective synthesis for the (？)-antipode of the pyrazinone marine alkaloid, hamacanthin A. J. Org. Chem. 2001, 66, 4865–4869, doi:10.1021/jo010265b.
[12]
Miyake, F.Y.; Yakushijin, K.; Horne, D.A. Synthesis of marine sponge bisindole alkaloids dihydrohamacanthins. Org. Lett. 2002, 4, 941–943, doi:10.1021/ol020002j.
[13]
Zoraghi, R.; Worrall, L.; See, R.H.; Strangman, W.; Popplewell, W.L.; Gong, H.; Samaai, T.; Swayze, R.D.; Kaur, S.; Vuckovic, M.; et al. Methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as a target for bis-indole alkaloids with antibacterial activities. J. Biol. Chem. 2011, 286, 44716–44725, doi:10.1074/jbc.M111.289033.
[14]
Caldwell, J.J.; Veillard, N.; Collins, I. Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases. Tetrahedron 2012, 68, 9713–9728, doi:10.1016/j.tet.2012.09.039.
[15]
Dar, A.C.; Shokat, K.M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Ann. Rev. Biochem. 2011, 80, 769–795, doi:10.1146/annurev-biochem-090308-173656.
[16]
Appelmann, I.; Liersch, R.; Kessler, T.; Mesters, R.; Berdel, W. Angiogenesis inhibition in cancer therapy: Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: Biological functions and role in malignancy. Recent Results Cancer Res. 2010, 180, 51–81, doi:10.1007/978-3-540-78281-0_5.
[17]
Koch, S.; Tugues, S.; Li, X.; Gualandi, L.; Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011, 437, 169–183, doi:10.1042/BJ20110301.
[18]
Zhou, Y.; Chen, Y.; Tong, L.; Xie, H.; Wen, W.; Zhang, J.; Xi, Y.; Shen, Y.; Geng, M.; Wang, Y.; et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J. Cell. Mol. Med. 2012, 16, 2321–2330, doi:10.1111/j.1582-4934.2012.01541.x.
[19]
Noble, M.E.M.; Endicott, J.A.; Johnson, L.N. Protein kinase inhibitors: Insights into drug design from structure. Science 2004, 303, 1800–1805, doi:10.1126/science.1095920.
[20]
Norman, R.A.; Toader, D.; Ferguson, A.D. Structural approaches to obtain kinase selectivity. Trends Pharmacol. Sci. 2012, 33, 273–278, doi:10.1016/j.tips.2012.03.005.
[21]
Sachsenmaier, C.; Schachtele, C. Integrated technology platform protein kinases for drug development in oncology. Biotechniques 2002, 33, S101–S106.
[22]
Heldin, C.H.; Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999, 79, 1283–1316.
[23]
Hodous, B.L.; Geuns-Meyer, S.; Hughes, P.; Albrecht, B.; Bellon, S.; Bready, J.; Caenepeel, S.; Cee, V.; Chaffee, S.; Coxon, A.; et al. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine tie-2 kinase inhibitor. J. Med. Chem. 2007, 50, 611–626, doi:10.1021/jm061107l.
[24]
Garuti, L.; Roberti, M.; Bottegoni, G. Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem. 2010, 17, 2804–2821, doi:10.2174/092986710791859333.
[25]
Peifer, C.; Stoiber, T.; Unger, E.; Totzke, F.; Schaechtele, C.; Marmé, D.; Brenk, R.; Klebe, G.; Schollmeyer, D.; Dannhardt, G. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J. Med. Chem. 2006, 49, 1271–1281, doi:10.1021/jm0580297.
[26]
Reiterer, G.; Yen, A. Platelet-derived growth factor receptor regulates myeloid and monocytic differentiation of HL-60 cells. Cancer Res. 2007, 67, 7765–7772, doi:10.1158/0008-5472.CAN-07-0014.
[27]
Johannes, E.; Horbert, R.; Schlosser, J.; Schmidt, D.; Peifer, C. Effective synthesis of 3,5-diaryl-(1H)-pyrazin-2-ones via microwave mediated ring closure. Tetrahedron Lett. 2013, 54, 4067–4072, doi:10.1016/j.tetlet.2013.05.095.
[28]
Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750–1759, doi:10.1021/jm030644s.
[29]
ProQinase Targeting Cancer. Available online: http://www.proqinase.com (accessed on 19 August 2013).
